Unul din obiectivele principale ale Life4me+ - să prevină apariția unor noi cazuri de infecție cu HIV, boli cu transmitere sexuală (TBS), hepatită C și tuberculoză

Aplicația permite stabilirea unei comunicări anonime între medici și persoane care au HIV. Îți permite să organizezi mai ușor programul de administrare a tratamentului și să setezi notificări personalizate și discrete

Toate știrile / Septembrie 2018

Arhivă

✕

26 septembrie 2018

10396

Immunotherapy of HIV passed the first phase of clinical trials

Immunotherapy of HIV passed the first phase of clinical trials

Preliminary results from phase I clinical trials demonstrated the safety and tolerability of cell therapy, including the introduction of artificially expanded T-cells with widely neutralizing antibodies (bNAbs) into the blood of HIV-positive volunteers who had previously ...

25 septembrie 2018

10508

American patients with hepatitis C will be available branded generics Gilead

American patients with hepatitis C will be available branded generics Gilead

On Monday, September 24, the American biopharmaceutical company Gilead Sciences Inc. said that it expects to launch in the US the production of a number of analogues for its own products. Among the applicants for the release are generic drugs for the treatment of hepatitis ...

24 septembrie 2018

10537

The number of heterosexuals with HIV in Australia is growing - experts

The number of heterosexuals with HIV in Australia is growing - experts

According to the latest statistics published today by the Kirby Institute (University of New South Wales, Australia), the number of diagnoses of "HIV infection" among Australian heterosexual men over the past five years has increased by 10%. The study showed that more than ...

18 septembrie 2018

9790

Scientists: HIV should be considered a major risk factor for cardiovascular disease

Scientists: HIV should be considered a major risk factor for cardiovascular disease

People living with HIV are twice as likely to suffer from cardiovascular disease (CVD), the results of a meta-analysis published in Circulation magazine show. According to researchers, over the past 20 years, the number of CVDs associated with HIV has tripled. Today this ...

17 septembrie 2018

10223

EMA will consider an application for the registration of an antiviral drug dolutegravir / lamivudine

EMA will consider an application for the registration of an antiviral drug dolutegravir / lamivudine

September 14 became known that the pharmaceutical company ViiV Healthcare, part of the GlaxoSmithKline structure, applied to the European Medicines Agency (EMA) for the registration of a two-component antiretroviral dolutegravir / lamivudine intended for the treatment of ...

17 septembrie 2018

13153

HIV-positive Norwegians may not get modern antiretroviral drugs

HIV-positive Norwegians may not get modern antiretroviral drugs

The Kingdom of Norway, which has maintained the status of the state with the world's highest human development index (HDI) for the last ten years and is the third largest on the planet by nominal GDP per capita, is on the verge of a crisis of underfunding the drug people ...

17 septembrie 2018

10237

ViiV submits two-drug regimen for HIV in Europe

ViiV submits two-drug regimen for HIV in Europe

#ViiV Healthcare has submitted an application in Europe for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.

3 septembrie 2018

10040

Early birth and weight loss: why Africa refuses dolutegravir?

Early birth and weight loss: why Africa refuses dolutegravir?

Antiretroviral regimens (ART) based on protease inhibitors or nucleoside reverse transcriptase inhibitors can cause early childbirth and low birth weight. This is reported by Aidsmap with reference to the Journal of Acquired Immune Deficiency Syndromes.